Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
AlaMab Therapeutics General Information
ALMB-0166 is in Phase 2 clinical trials for acute spinal cord injury, while ALMB-0168 is in Phase 1 for osteosarcoma. As of 2024, both drugs have received approval for first-in-human clinical trials in Australia. ALMB-0166 has been granted Orphan-Drug Designation by the U.S. FDA for acute spinal cord injury, and ALMB-0168 has received Rare Pediatric Disease Designation from the FDA.
Contact Information
Primary Industry
Biotech
Corporate Office
Princeton, New Jersey
United States
United States
Drug Pipeline
ALMB-0166
Phase 1Key Partnerships
University of Texas
AlaMab Therapeutics Funding
No funding data available
To view AlaMab Therapeutics's complete valuation and funding history, request access »